

**32692**  
Customer Number

# Request for Continued Examination (RCE) Transmittal

## CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR § 1.8(a)]

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being:

- ☒ transmitted to United States Patent and Trademark Office on the date shown below via the Office electronic filing system.
- ☐ deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
- ☐ transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at 571-273-8300 or if filing with a Petition to Withdraw from Issue to: 571-273-0025.

June 16, 2010 /Chris Johnson/  
Date Signed by: Chris Johnson

First Named Inventor: Roehrig, Mark A  
Application No. : 10/823328 Confirmation No.: 4482  
Filed: 13-APR-2004  
Title: Transdermal Drug Delivery Device with Translucent Inorganic Barrier Layer

**This is a Request for Continued Examination (RCE) under 37 CFR § 1.114 of the above-identified application.**

**1. Submission required under 37 CFR § 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless Applicant instructs otherwise. If Applicant does not wish to have any previously filed unentered amendment(s) entered, Applicant must request non-entry of such amendment(s).

- a. ☐ Previously submitted. If a final Office Action is outstanding, any amendments filed after the final Office Action may be considered as a submission even if this box is not checked.
- i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_.
- ii. ☐ Other:
- b. ☒ Enclosed:
- i. ☒ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)/Supplemental IDS
- iv. ☐ Other:

## 2. Miscellaneous

- a. Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
- b. Other \_\_\_\_\_

**3. Fees:** The RCE fee (\$810.00) under 37 CFR § 1.17(e) is required by 37 CFR § 1.114 when the RCE is filed.

- ☒ The RCE fee required under 37 CFR § 1.17(e) will be made at the time of submission via EFS-Web. In the event fees are not or cannot be paid at the time of EFS-Web submission, please charge any fees under 37 CFR § 1.17 which may be required to Deposit Account No. 13-3723.
- ☐ The Director is authorized to charge the RCE fee required by 37 CFR § 1.17(e) to Deposit Account No. 13-3723.
- ☒ Please charge any additional fees associated with the prosecution of this application to Deposit Account No. 13-3723. This authorization includes the fee for any necessary extension of time under 37 CFR § 1.136(a). To the extent any such extension should become necessary, it is hereby requested.
- ☒ Please credit any overpayment to the same deposit account.

**4. ☐ A Request for Extension of Time is being filed concurrently.**

Respectfully submitted,

June 15, 2010

Date

By: /Robert W. Sprague/

Robert W. Sprague, Reg. No.: 30,497

Telephone No.: 651-733-4247

Office of Intellectual Property Counsel  
3M Innovative Properties Company  
Facsimile No.: (651) 736-3833